Clinical trials
Progression clinical trials
Below are recruiting progression clinical trials, each written for real people, not researchers. We’re tracking 721 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06855368Recruiting
Biomarkers for tracking dementia progression
This study looks at biological markers to monitor how dementia changes over time. It may help understand the disease better in people with early Alzheimer's or mild cognitive impairment.
RomaAges 18 years+ - NCT06856213RecruitingPhase 2
Cetuximab with or without weekly paclitaxel for head and neck cancer
This study tests whether adding the chemotherapy drug paclitaxel (Taxol) to the targeted therapy cetuximab (Erbitux) is more effective than cetuximab alone for head and neck cancer that has progressed after initial immunotherapy and chemotherapy. Researchers want to see if the combination can help shrink tumors or slow the disease.
Santiago de Compostela, A CoruñaAges 18 years+ - NCT06863194RecruitingPhase 1/Phase 2
Probiotics and kidney disease progression trial
This trial tests whether taking a probiotic supplement can slow down the decline of kidney function in people with moderate chronic kidney disease (CKD stages 3 and 4). If you have stable kidney disease and are not already taking probiotics, joining this study could help researchers find a new way to protect your kidneys.
Al Mansurah, DakahliyaAges 18 years+ - NCT06863311RecruitingPhase 2
Trial of zanzalintinib with immunotherapy for advanced kidney cancer
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06878664RecruitingPhase 3
Lu177-Dotatate vs standard care for slow-growing midgut neuroendocrine tumors
This trial tests whether a radioactive drug called Lu177-Dotatate (PRRT) works better than usual care for people with slow-growing, advanced midgut neuroendocrine tumors (NETs). It may help shrink or slow the growth of tumors when you also get somatostatin analog therapy.
Caen, CaenAges 18 years+ - NCT06896162Recruiting
Genetic test to guide first or second treatment for advanced cancer
This study looks at whether using a detailed genetic test of your tumor can help pick the best first or second treatment for advanced lung, colon, breast, or bladder cancer. The goal is to see if this personalized approach helps people live longer.
Chapel Hill, North CarolinaAges 18 years+ - NCT06899360Recruiting
Age-related macular degeneration progression study
This study tracks how age-related macular degeneration (AMD) progresses over time and looks at factors that might affect your vision and quality of life. By participating, you'll help researchers understand more about AMD and what might predict better or worse outcomes.
Udine, UDAges 50–120 - NCT06911333RecruitingPhase 1/Phase 2
A new drug for advanced solid tumors that have stopped responding to treatment
This trial tests a new drug called AD1208 for people with advanced solid tumors that have grown despite previous treatments. The goal is to see if the drug can help where other options no longer work or are not suitable.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06919380RecruitingPhase 1
Mist from stem cell byproducts for autoimmune lung disease
This study tests a new type of treatment using a mist (nebulized) made from stem cell byproducts to see if it can safely help people with a rare autoimmune lung disease. It is for patients with anti-MDA5 positive dermatomyositis who have a fast-progressing lung condition.
Guangzhou, GuangdongAges 18–75 - NCT06922526Recruiting
Pacemaker and tricuspid valve health: long-term outcomes
This study looks at how pacemakers and similar heart devices affect the tricuspid valve over time and whether that leads to worse health outcomes. It may help you understand if your device is causing long-term changes.
JinanAges 18 years+ - NCT06922994RecruitingPhase 2
Testing atorvastatin for arrhythmogenic cardiomyopathy
This trial tests if a common cholesterol medicine, atorvastatin, can slow the progression of arrhythmogenic cardiomyopathy, a genetic heart condition that can cause abnormal heart rhythms. If you have this condition, joining this study may help researchers find a new way to protect your heart.
Pavia, PVAges 18 years+ - NCT06923709RecruitingPhase 2
Amiloride for slowing kidney disease progression
This trial tests if the drug amiloride can help slow down chronic kidney disease. It may be an option if you have moderate kidney function and high protein in your urine.
OdenseAges 18 years+ - NCT06936046RecruitingPhase 2
Enhanced treatment for newly diagnosed GBM with partial resection or early progression
This trial tests a stronger combination of treatments given after surgery for people with glioblastoma (GBM) that was only partially removed or that starts growing again quickly. It aims to see if this approach can help control the tumor better. You may be eligible if you are newly diagnosed, over 18, have good organ function, and do not have other serious health issues.
HangzhouAges 18 years+ - NCT06943326Recruiting
How food given through a tube affects recovery in sepsis patients
This trial tests if the type of tube feeding given to sepsis patients in the ICU can affect their recovery. It aims to find the best diet to help fight the infection and prevent complications.
SanliurfaAges 18 years+ - NCT06949865Recruiting
AI-enhanced levodopa challenge test for parkinsonism
This study uses artificial intelligence (AI) to improve a standard test for parkinsonism called the levodopa challenge test. It may help doctors better understand how your movement symptoms respond to levodopa, a common Parkinson's medication.
BeijingAges 50–75 - NCT06972628RecruitingPhase 2
177Lu-PSMA-617 for advanced prostate cancer with bone spread
This trial tests a radioactive drug called 177Lu-PSMA-617 to see if it can help men with metastatic castration-resistant prostate cancer that has spread to the bones in a specific pattern (superscan). It's for patients who have already tried hormone therapy and have PSMA-positive tumors.
Houston, TexasAges 18 years+ - NCT06975332Recruiting
Targeted radiation therapy for recurrent high-grade glioma
This trial tests a new radiation treatment that targets tumor cells directly. It may help people with a specific type of aggressive brain tumor that has grown after standard treatments.
Warsaw, PolandAges 18–80 - NCT06990087RecruitingPhase 2
T-cell therapy for progressive multifocal leukoencephalopathy (PML)
This trial tests a T-cell therapy for people with PML, a rare brain infection. It aims to boost your immune system to fight the virus causing PML. You may be eligible if you have PML not caused by HIV, natalizumab, or certain recent treatments.
München, BavariaAges 18 years+ - NCT06995170Recruiting
Polyamines and IBD progression study
This study looks at how certain natural chemicals called polyamines relate to the activity of inflammatory bowel disease (IBD). It aims to understand if these chemicals can help predict disease progression.
Xi'an, ShaanxiAges 18–65 - NCT06998108RecruitingPhase 3
A new drug with fulvestrant for HR+/HER2- advanced breast cancer
This trial tests a new investigational drug called BEBT-209 combined with fulvestrant (a hormone therapy) versus placebo with fulvestrant for people with a type of breast cancer that is hormone receptor-positive and HER2-negative. It is for those whose cancer has worsened after previous hormone therapy and has spread locally or to other parts of the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07003542RecruitingPhase 2
Sitagliptin for people with high-grade brain tumors
This trial tests whether sitagliptin, a medicine usually used for diabetes, can help people with a fast-growing type of brain tumor (grade 4 glioma). You will take sitagliptin before your planned surgery, and researchers will study how it affects your tumor.
Cleveland, OhioAges 18 years+ - NCT07008716RecruitingPhase 3
Omitting CTV for primary tumor in limited-stage small cell lung cancer
This trial tests whether treating the main tumor alone, without the nearby lymph nodes, can work as well in limited-stage small cell lung cancer after initial chemotherapy. You may qualify if you have not had disease progression after 2-4 cycles of standard chemo and meet other health criteria.
Guangzhou, GuangdongAges 18–75 - NCT07010263RecruitingPhase 3
AK112 for limited-stage small cell lung cancer after chemoradiation
This study tests a new drug called AK112 (a bispecific antibody that blocks both PD-1 and VEGF) as a consolidation treatment to help prevent your limited-stage small cell lung cancer from coming back after you've finished chemoradiation. It's for people whose cancer has not grown following concurrent chemotherapy and radiation.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07017816RecruitingEarly Phase 1
Gene therapy, checkpoint inhibitor, and radiation for children with brain cancer
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Washington D.C., District of ColumbiaAges 3–21
Hear when a new Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progression?
- Yes. Clin2 currently lists 721 recruiting progression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.